• Page: 1527
• First Published: 06 October 2010

Is radioembolization ready for the barcelona clinic liver cancer staging system?^†‡

• Pages: 1528-1530
• First Published: 29 October 2010

Association of anti-E1E2 antibodies with spontaneous recovery or sustained viral response to therapy in patients infected with hepatitis C virus^†

• Pages: 1531-1542
• First Published: 29 October 2010

Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1^†

• Pages: 1543-1552
• First Published: 29 October 2010

Anti–tumor necrosis factor α treatment promotes apoptosis and prevents liver regeneration in a transgenic mouse model of chronic hepatitis C^†

• Pages: 1553-1563
• First Published: 29 October 2010

Frequent multiple hepatitis C virus infections among injection drug users in a prison setting^†

• Pages: 1564-1572
• First Published: 29 October 2010

Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6^†‡

• Pages: 1573-1580
• First Published: 29 October 2010

Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro^†

• Pages: 1581-1589
• First Published: 19 August 2010

Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients^†

• Pages: 1590-1599
• First Published: 19 August 2010

Impact of hepatitis B virus surface protein mutations on the diagnosis of occult hepatitis B virus infection^†

• Pages: 1600-1610
• First Published: 29 October 2010

Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen–positive patients^†

• Pages: 1611-1620
• First Published: 19 August 2010

Activation of LKB1-Akt pathway independent of phosphoinositide 3-kinase plays a critical role in the proliferation of hepatocellular carcinoma from nonalcoholic steatohepatitis^†

• Pages: 1621-1631
• First Published: 29 October 2010

Liver-specific suppressor of cytokine signaling-3 deletion in mice enhances hepatic insulin sensitivity and lipogenesis resulting in fatty liver and obesity1

• Pages: 1632-1642
• First Published: 29 October 2010

Functional and morphological vascular changes in pediatric nonalcoholic fatty liver disease^†

• Pages: 1643-1651
• First Published: 29 October 2010

Coffee reduces liver damage in a rat model of steatohepatitis: The underlying mechanisms and the role of polyphenols and melanoidins^†

• Pages: 1652-1661
• First Published: 19 August 2010

Mutation analysis and characterization of alternative splice variants of the Wilson disease gene ATP7B^†

• Pages: 1662-1670
• First Published: 29 October 2010

A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis^†

• Pages: 1671-1779
• First Published: 29 October 2010

• Pages: 1680-1689
• First Published: 29 October 2010

Overlapping high-resolution copy number alterations in cancer genomes identified putative cancer genes in hepatocellular carcinoma^†

• Pages: 1690-1701
• First Published: 29 October 2010

A novel GSK-3 beta–C/EBP alpha–miR-122–insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma^†

• Pages: 1702-1712
• First Published: 29 October 2010

Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis^†

• Pages: 1713-1722
• First Published: 29 October 2010

Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: The importance of tumor cell differentiation^†

• Pages: 1723-1730
• First Published: 19 August 2010

MicroRNA-125b suppressesed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2

• Pages: 1731-1740
• First Published: 19 August 2010

Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival^†‡

• Pages: 1741-1749
• First Published: 31 August 2010

Age dependence of oval cell responses and bile duct carcinomas in male fischer 344 rats fed a cyclic choline-deficient, ethionine-supplemented diet^†

• Pages: 1750-1757
• First Published: 29 October 2010

Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid–induced cholestasis in rat liver^†‡

• Pages: 1758-1768
• First Published: 20 August 2010

The fractalkine receptor CX₃CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes^†

• Pages: 1769-1782
• First Published: 29 October 2010

Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension^†

• Pages: 1783-1790
• First Published: 29 October 2010

Polymerase γ Gene POLG determines the risk of sodium valproate-induced liver toxicity^†‡

• Pages: 1791-1796
• First Published: 29 October 2010

Liver X receptor α and farnesoid X receptor are major transcriptional regulators of OATP1B1^†

• Pages: 1797-1807
• First Published: 29 October 2010

• Pages: 1808-1818
• First Published: 29 October 2010

Adenosine triphosphate release and purinergic (P2) receptor–mediated secretion in small and large mouse cholangiocytes^†

• Pages: 1819-1828
• First Published: 29 October 2010

The role of intestinal endotoxin in liver injury: A long and evolving history^†

• Pages: 1829-1835
• First Published: 20 August 2010

Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis^†

• Pages: 1836-1846
• First Published: 20 September 2010

Early transjugular intrahepatic portosystemic shunt in patients with cirrhosis and variceal bleeding^†

• Pages: 1847-1850
• First Published: 29 October 2010

Defining the quality characteristics of endoscopy for acute variceal hemorrhage in cirrhosis^†

• Pages: 1850-1851
• First Published: 29 October 2010

Nonalcoholic fatty liver disease: is it all in the genes?^†

• Pages: 1851-1854
• First Published: 29 October 2010

Massive hepatomegaly and involvement by Janus kinase 2–positive myeloproliferative neoplasm^†

• Pages: 1855-1856
• First Published: 20 August 2010

Application of the 2010 American Association for the study of liver diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis^†

• Page: 1857
• First Published: 20 August 2010

Reply:^†

• Pages: 1857-1858
• First Published: 01 September 2010

On the mercapturic acid pathway of nitric oxide: is S-nitrosoglutathione present in the bile?^†

• Pages: 1858-1859
• First Published: 20 August 2010

Reply:^†

• Pages: 1859-1860
• First Published: 07 September 2010

Observed and calculated interleukin-28B genotype frequencies in hepatitis C virus infection^†

• Pages: 1860-1861
• First Published: 07 September 2010

Reply:^†

• Pages: 1861-1862
• First Published: 17 September 2010

Time trends in hospitalization and discharge status for cirrhosis and portal hypertension in the united states^†

• Page: 1862
• First Published: 14 September 2010

Reply:^†

• Page: 1863
• First Published: 30 September 2010

Screening for hepatocellular carcinoma: From lack of evidence to common sense^†

• Pages: 1863-1864
• First Published: 29 October 2010

Vitamin D controls T cell activation: Implication for causal association between vitamin D deficiency and fibrosis in chronic hepatitis C^†

• Page: 1864
• First Published: 29 October 2010

Complications of alcoholic liver cirrhosis: Active assessment by endoscopy and sonography^†

• Pages: 1864-1865
• First Published: 29 October 2010

Hypouricemic therapy: A novel potential therapeutic option for nonalcoholic fatty liver disease^†

• Pages: 1865-1866
• First Published: 29 October 2010

Suggestion of a dual-functional agent for future trials in nonalcoholic fatty liver disease^†

• Pages: 1866-1867
• First Published: 29 October 2010

Pegylated interferon and ribavirin in real life: Efficacy versus effectiveness^†

• Page: 1867
• First Published: 29 October 2010